Insulin glulisine is used to treat type 1 or type 2 diabetes in adults and type 1 diabetes children who are at least 4 years old. Do NOT reuse needles.
Do not share needles insulin pens or syringes with others even if the needle is changed.
Glulisine. Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. Substances that may enhance the blood-glucose-lowering activity and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products angiotensin converting enzyme ACE inhibitors disopyramide fibrates fluoxetine monoamine oxidase inhibitors MAOIs pentoxifylline. Insulin glulisine and insulin human are equipotent on a unit-for-unit basis.
The primary efficacy measure was change in adjusted mean. Insulin glulisine has a more rapid onset and shorter duration of action compared with insulin human after subcutaneous admin. The rapid-acting insulin analogue insulin glulisine glulisine was compared with insulin lispro lispro for efficacy and safety in Japanese patients with type 1 diabetes mellitus T1DM using insulin glargine glargine as basal insulin.
Total daily insulin requirement may vary and is usually between 05-1 unitkgday. You may give other people a serious infection or get a serious infection from them. Insulin glulisine bisa dicampur dengan insulin NPH isophane insulin dalam alat suntik yang sama tetapi harus disuntik dengan segera.
A rapid-acting insulin analog whose amino acid sequence differs from that of human insulin by the substitution of lysine for asparagine and glutamic acid for lysine in the B chain used in the treatment of type 1 and type 2 diabetes. Jika dicampur dengan insulin NPH ambil insulin glulisine. Research design and methods.
A rapid-acting insulin analog whose amino acid sequence differs from that of human insulin by the substitution of lysine for asparagine and glutamic acid for lysine in the B chain used in the treatment of type 1 and type 2 diabetes. Lispro Eli Lilly aspart Novo Nordisk and glulisine Sanofi insulins are produced by amino acid substitutions in the C-terminal region of the B-chain that reduce the affinity of insulin molecules to self-aggregate into hexamers. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times.
Insulin glulisine has a more rapid onset of action and a shorter duration of action than regular human insulin. It was developed by Sanofi-Aventis and is sale under the trade name Apidra. Insulin glulisine is used to improve blood sugar control in adults and children with diabetes mellitus.
Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. Blood glucose monitoring is essential in all patients receiving insulin therapy. Dosage must be individualized.
This was an open randomized parallel-group comparative non-inferiority study. Insulin glulisine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Insulin glulisine is a rapid acting human insulin analog produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli K12.
In total 876 relatively well-controlled patients with type 2 diabetes mean HbA1c 755. This study compared the safety and efficacy of glulisine with regular human insulin RHI in combination with NPH insulin. Do not use Apidra if you have low blood sugar reaction or if you are allergic to insulin glulisine or any of the ingredients in Apidra.
These modifications allow more rapid absorption of the analog into the bloodstream after subcutaneous injection. Glulisine and particularly close monitoring. Controlling high blood sugar helps prevent kidney damage blindness nerve.
Insulin glulisine may also be used for purposes not listed in this medication guide. For insulin glulisine Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump.